SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending as investors weigh strong earnings expectations and ongoing digital payments growth against regulatory headwinds, including proposed caps on credit card interest rates. The community is actively debating the stock's resilience, focusing on whether high-quality cash generation and strategic blockchain initiatives can offset competitive and policy-driven risks.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

ChainLink is seeing increased community chatter as it remains a central pillar in institutional RWA tokenization, with investors weighing its long-term infrastructure utility against ongoing frustration with its lagging price performance. While proponents point to growing adoption by major financial institutions and the potential for a breakthrough with upcoming regulatory clarity, others are increasingly vocal about the token's stagnant price action and underwhelming historical returns.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF is trending as investors favor broad-market index funds over individual stock picking to navigate market volatility and macro uncertainty. The community is actively discussing the benefits of a set-and-forget strategy for long-term compounding, with many highlighting the fund's low expense ratio and comprehensive exposure to the U.S. economy as a reliable safe haven amidst fluctuating market conditions.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck & Co. is trending due to intensified buyout speculation as the pharmaceutical giant navigates the looming patent expiration of its blockbuster drug, Keytruda, while investors debate the potential acquisition of promising oncology platform developers. Community discussion is heavily focused on the competitive landscape of the biotech sector, with participants analyzing buyout valuations and identifying potential targets like Sellas Life Sciences that could bolster Merck's pipeline.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining traction as community members highlight its role in providing high-speed data feeds for real-world assets and major institutional partners. Enthusiasts are actively debating the network's shift toward a paid service model and its potential as a critical infrastructure layer alongside established oracle competitors.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2024 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as investors digest acquisition interest from the Apollo-backed Legendary Entertainment, fueling ongoing community speculation about a potential buyout. Market participants are actively debating the viability of a takeover, citing the studio's deep content library and recent ownership restructuring as key drivers for a premium valuation.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending following the publication of groundbreaking Phase 3 trial data for daraxonrasib, which demonstrated a significant survival benefit in metastatic pancreatic cancer. The oncology community is actively discussing the drug's potential as a new standard of care, leading to heavy institutional interest and speculation regarding its value as a premier target for large-scale pharmaceutical acquisitions.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as investors focus on the commercial launch momentum of its FDA-approved gene therapy, ZEVASKYN, and its pivot toward near-term profitability. Community discussion highlights the stock's potential as a highly undervalued play supported by a strong cash position, low debt, and an expanding network of qualified treatment centers.

TELUS Corp. is a telecommunications company, which engages in the provision of telecommunication services and products primarily for wireless and wireline voice and data. It operates through TELUS Technology Solutions (TTech) and Digitally-led Customer Experiences–TELUS International (DLCX) segments. The TTech segment includes network revenues and equipment sales arising from mobile technologies, data revenues, healthcare software and technology solutions, voice and other telecommunications services revenues, and equipment sales. The DLCX segment is composed of digital customer experience and digital-enablement transformation solutions, including artificial intelligence and content management solutions, provided by TELUS International. The company was founded on October 4, 1990 and is headquartered in Vancouver, Canada.

Telus Corp.

Telus is seeing significant volatility as investors debate the impact of potential dividend adjustments, rising debt, and ongoing cost-cutting measures. The community remains deeply divided, with some highlighting the company's long-term value and AI infrastructure investments, while others express frustration over share dilution and the sustainability of payouts.

Bending Spoons SpA engages in the conviction that operational excellence enables efficient growth through acquisitions. The firm acquire digital businesses, implement deep transformations and ongoing optimizations to sustainably expand earnings, and reinvest in additional acquisitions, thereby continuing the compounding cycle. The performance is driven by platform?comprising people, proprietary technologies, and proprietary data?and reflects intense focus on achieving exceptional talent density, cultural strength, and technical capabilities. The company was founded by Luca Ferrari, Francesco Patarnello and Matteo Danieli in 2013 and is headquartered in Milan, Italy.

Bending Spoons S.p.A.

Bending Spoons is attracting intense market attention following its recent initial public offering, with investors debating the company's aggressive strategy of acquiring legacy digital platforms and optimizing them through artificial intelligence. The community remains sharply divided, with some betting on the firm's growth potential while many vocal critics express skepticism regarding its valuation, business model, and accessibility on popular retail trading platforms.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
